Comparison of PPI with H2RA plus egualen sodium combination therapy for the artificial ulcer after ESD

Comparison of PPI with H2RA plus egualen sodium combination therapy for the artificial ulcer after ESD - Comparison of PPI with H2RA plus egualen sodium combination therapy for the artificial ulcer after ESD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005429

Enrollment

Registered

2011-04-13

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early gastric cancer,Gastric adenoma

Interventions

Administration of H2RA(Famotidine)+ egualen sodium for ESD-induced ulcer Administration of PPI (Lansoprazole) for ESD-induced ulcer

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were diagnosed as early gastric cancer or gastric adenoma and are considered as the indication of endoscopic submucosal dissection.

Exclusion criteria

Exclusion criteria: 1)Patients who have anticoagulant or antiplatelet therapy 2)Patients who had total gastrectomy during the course observation. 3)Women during pregnancy or breast-feeding. 4)Patients who have sever liver, renal disease,

Design outcomes

Primary

Measure	Time frame
Endoscopic evaluations:The primary endopoint is the ulcer healing at 8 weeks after ESD.	—

Secondary

Measure	Time frame
Endoscopic evaluations:ulcer healing rate Symptom	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026